The company touted the recent spate of positive payor coverage decisions it has seen for its ConfirmMDx and SelectMDx prostate cancer tests.
The deal suggests the company is making steady progress toward its goal of signing coverage deals with all major private payors by year end.
The insurer operates Blue Cross and Blue Shield plans in Illinois, Montana, New Mexico, Oklahoma, and Texas, and will now cover ConfirmMDx for its customers.
The colon cancer test is now available through Tricare for 9.4 million active duty, reserve, and National Guard personnel, as well as veterans and their dependents.
The positive insurance coverage decision for ConfirmMDx is one of several the company has received in recent months.
The researchers also plan to analyze how payors make coverage decisions for NGS-based gene panels, exome, and whole-genome sequencing clinical tests.
The positive coverage determination is one of several the company has received in recent months from various insurance companies for the ConfirmMDx test.
The in-network agreement gives the health plan's 8 million members access to Trovagene's full menu of liquid biopsy tests.
At HudsonAlpha's Genomic Medicine Conference University of North Carolina's Anya Prince discussed insurance coverage of genetic tests and preventive care.
MDxHealth said the positive medical policy decision adds to growing recognition of the ConfirmMDx test's value for improving patient outcomes.
Google's Project Nightingale has collected health information on millions of Americans, according to the Wall Street Journal.
An opinion piece at The Hill criticizes the proposed plan to collect DNA samples from migrants at the US border.
Nature News writes that women in chemistry are less likely to have their manuscripts accepted for publication.
In PNAS this week: tRNA fragment signature for chronic lymphocytic leukemia, genomic sites sensitive to ultraviolet radiation in melanocytes, and more.